Literature DB >> 8611403

A study on the levels of calmodulin and DNA in human lung cancer cells.

G X Liu1, H F Sheng, S Wu.   

Abstract

In order to study the role of calmodulin (CaM) in the proliferation of lung cancer cells, the CaM level of the specimens of 40 cases of primary lung cancers and the DNA content of the specimens of 35 cases of primary lung cancers were determined with phosphodiesterase assay and flow cytometry respectively. It was found that the CaM level of lung cancers was significantly higher than that of host lungs, benign lung diseases and normal lungs (p<0.001) and that it was significantly correlated with the histopathological grading and TNM staging of the lung cancers. It was also found that the cellular DNA content of lung cancers, like the CaM level, was also significantly higher than that of benign lung diseases and normal lungs (p<0.001). There was a significant positive correlation between the cellular DNA content and tissue CaM level in lung cancers (r=0.885). It is believed that CaM plays an important role in the proliferation of lung cancer cells through the mechanism of the promotion of an uncontrolled synthesis of DNA in the cells. Consequently, it is inferred that CaM antagonists may be tried as a chemotherapeutic agent for lung cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8611403      PMCID: PMC2074263          DOI: 10.1038/bjc.1996.160

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial.

Authors:  R L Miller; R M Bukowski; G T Budd; J Purvis; J K Weick; K Shepard; K K Midha; R Ganapathi
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

2.  Enhanced bleomycin-induced DNA damage and cytotoxicity with calmodulin antagonists.

Authors:  J S Lazo; W N Hait; K A Kennedy; I D Braun; B Meandzija
Journal:  Mol Pharmacol       Date:  1985-03       Impact factor: 4.436

Review 3.  Calmodulin: a potential target for cancer chemotherapeutic agents.

Authors:  W N Hait; J S Lazo
Journal:  J Clin Oncol       Date:  1986-06       Impact factor: 44.544

Review 4.  Cations and calmodulin in normal and neoplastic cell growth regulation.

Authors:  R A Hickie; J W Wei; L M Blyth; D Y Wong; D J Klaassen
Journal:  Can J Biochem Cell Biol       Date:  1983-08

5.  Assay of calmodulin by Ca2+-dependent phosphodiesterase.

Authors:  R W Wallace; E A Tallant; W Y Cheung
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

6.  Positive correlation between calmodulin content and hepatoma growth rates.

Authors:  J W Wei; H P Morris; R A Hickie
Journal:  Cancer Res       Date:  1982-07       Impact factor: 12.701

7.  Calcium: calmodulin and cancer.

Authors:  W E Criss; S Kakiuchi
Journal:  Fed Proc       Date:  1982-05

8.  The role of calmodulin in human renal cell carcinoma.

Authors:  T D Moon; J E Morley; R L Vessella; A S Levine; G Peterson; P H Lange
Journal:  Biochem Biophys Res Commun       Date:  1983-07-29       Impact factor: 3.575

9.  Inhibition of growth of leukemic cells by inhibitors of calmodulin: phenothiazines and melittin.

Authors:  W N Hait; L Grais; C Benz; E C Cadman
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  Increased content of calmodulin in human leukemia cells.

Authors:  D Takemoto; C Jilka
Journal:  Leuk Res       Date:  1983       Impact factor: 3.156

View more
  7 in total

1.  Regulation of calcium signaling in lung cancer.

Authors:  Haihong Yang; Qi Zhang; Jianxing He; Wenju Lu
Journal:  J Thorac Dis       Date:  2010-03       Impact factor: 2.895

Review 2.  The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas.

Authors:  Ruth Nussinov; Serena Muratcioglu; Chung-Jung Tsai; Hyunbum Jang; Attila Gursoy; Ozlem Keskin
Journal:  Mol Cancer Res       Date:  2015-06-17       Impact factor: 5.852

3.  Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice.

Authors:  Min Wu; Sahn-Ho Kim; Indrani Datta; Albert Levin; Gregory Dyson; Jing Li; Stephanie Kaypee; M Mahadeva Swamy; Nilesh Gupta; Ho Jeong Kwon; Mani Menon; Tapas K Kundu; G Prem-Veer Reddy
Journal:  Oncotarget       Date:  2015-03-20

4.  Identification of CALM as the potential serum biomarker for predicting the recurrence of nasopharyngeal carcinoma using a mass spectrometry-based comparative proteomic approach.

Authors:  Huiling Meng; Xiaodong Zhu; Ling Li; Zhongguo Liang; Xiaoyu Li; Xinbin Pan; Fanyan Zeng; Song Qu
Journal:  Int J Mol Med       Date:  2017-08-09       Impact factor: 4.101

5.  The interactome and spatial redistribution feature of Ca2+ receptor protein calmodulin reveals a novel role in invadopodia-mediated invasion.

Authors:  Tao Li; Li Yi; Long Hai; Haiwen Ma; Zhennan Tao; Chen Zhang; Iruni Roshanie Abeysekera; Kai Zhao; Yihan Yang; Wei Wang; Bo Liu; Shengping Yu; Luqing Tong; Peidong Liu; Meng Zhu; Bingcheng Ren; Yu Lin; Kai Zhang; Cheng Cheng; Yubao Huang; Xuejun Yang
Journal:  Cell Death Dis       Date:  2018-02-20       Impact factor: 8.469

6.  Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment.

Authors:  Pareesa Kamgar-Dayhoff; Tinatin I Brelidze
Journal:  Oncotarget       Date:  2021-07-06

7.  Upregulation of c-FLIP-short in response to TRAIL promotes survival of NSCLC cells, which could be suppressed by inhibition of Ca2+/calmodulin signaling.

Authors:  V O Kaminskyy; O V Surova; T Piskunova; I B Zborovskaya; E M Tchevkina; L Andera; B Zhivotovsky
Journal:  Cell Death Dis       Date:  2013-03-07       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.